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Background/aim: Hepatitis B virus (HBV) infection is the leading cause of liver fibrosis (LF). The prognosis and management of
patients with chronic hepatitis B virus depend on the amount and progression of liver fibrosis. Angiopoietin-like protein 2 (Angptl2) is
not only a chronic inflammatory mediator, but also a tissue-remodeling factor. The aim of this study is to explore the predictive value of
Angptl2 in different fibrosis stages in patients chronically infected with HBV.
Materials and methods: Eighty patients with chronic HBV infection undergoing Fibroscan were included. Serum concentrations of
Angptl2 were detected using a commercial ELISA kit.
Results: Angptl2 levels were significantly associated with liver fibrosis stages (P = 0.02). The area under the curve (AUC) of Angptl2
for distinguishing patients who showed significant fibrosis (F2–F4) was 70.2%. Angptl2 with fibrosis-4 (FIB-4) and Angptl2 with AST/
platelets ratio (APRI) performed best with an AUC of 92.5%.
Conclusion: In patients with chronic HBV infection, Angptl2 level represents a potential biomarker independently associated with
fibrosis stages. The combination of Angptl2 with FIB-4 or Angptl2 with APRI performed better than the existing models for diagnosing
significant fibrosis.
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1. Introduction
Chronic hepatitis B (CHB) is defined as chronic
necroinflammatory disease. It is the 10th leading cause
of death in the world [1]. Fibrosis is a dynamic process
characterized by excessive accumulation of extracellular
matrix (ECM) proteins, resulting in pathological collagen
deposition [2]. Hepatic fibrogenesis begins with the
stimulation of inflammatory immune cells to secrete
cytokines [3]. Typical wound healing for chronic liver
diseases is defined by an increase in the expression of
some cytokines, growth factors, and metalloproteinases
with proangiogenic action [4]. In advanced stages, the
liver contains approximately 6 times more ECM than
normal [5]. Liver fibrosis is a middle stage in the course of
chronic HBV infection, which will develop into cirrhosis
and eventually hepatocellular carcinoma (HCC) if not
treated at the early stage. The risk of developing cirrhosis
depends on the degree or stage of fibrosis in the liver [6].
Fibroscan is a noninvasive test that replaces liver biopsy

[7]. Liver biopsy merely offers a snapshot image of the
underlying histology at a given time point [8]. Biomarkers
of fibrosis are commonly divided into two main categories:
direct and indirect markers. Direct and indirect markers
can be used alone or more frequently in combination to
increase the diagnostic reliability [9,10]. Cytokines and
regulatory molecules are essential mediators in the host’s
adaptive immune response to HBV and viral clearance.
Imbalance in cytokine production plays a key role in the
development of liver damage, necroinflammation, and
subsequent fibrosis [11]. However, only a few studies have
addressed the diagnostic accuracy of fibrosis-associated
cytokines [12]. Angiopoietin-like protein 2 (Angptl2)
is a glycoprotein [13] belonging to the angiopoietin-like
family [14]. It is secreted by hepatocytes [15]. Excess
Angptl2 signaling causes chronic inflammation and
subsequently pathological irreversible tissue remodeling
[16]. The systemic inflammation is the obvious link
between an increase in circulating levels of Angptl2 and
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chronic diseases. In chronic low-grade inflammation,
sustained overproduction of proinflammatory Angptl2
could contribute [17]. The regulatory X protein of hepatitis
B (HBx) activates the transcription factors nuclear factor
kappa beta (NF-κB), which promotes HBV replication
[18,19]. Angptl2 also activates the integrin α5β1/Rac1/
NFκB-dependent pathway, subsequently resulting in
transcription of several proinflammatory cytokines
[20,21]. Angptl2 signaling through integrin a5b1 increases
tissue inflammation and ECM remodeling, resulting in
activation of tissue remodeling [16,20]. It contributes to
the acceleration of tissue fibrosis through activation of
the transforming growth factor beta (TGF-β1)/Smad
signaling pathway, like in renal fibrosis [22]. High Angptl2
concentrations are a marker of cellular dysfunction,
associated with systemic inflammation [20]. The aim of
this study is to explore the predictive value of Angptl2 in
different fibrosis stages in patients chronically infected
with HBV.
2. Materials and methods
This study population consisted of ten control volunteers
and eighty patients with CHB infection of different
fibrosis stages from the National Hepatology and
Tropical Medicine Research Institute. HBV patients
were diagnosed based on positive HBV surface antigen
(HBsAg) and fluctuated alanine aminotransferase (ALT)
and HBV-DNA (≥2000 IU/mL). Full clinical, biochemical,
and hematological data were recorded for all patients. The
patients were personally asked about the time of their
infection, whether they were being treated or not, and
the type of treatment prescribed for them. Liver stiffness
was measured by Fibroscan. HBV cases were divided into
fibrosis stages from F0 to F4. Noninvasive markers of
fibrosis, including APRI, AST/ALT ratio (AAR), and FIB4 score were calculated. Serum Angptl2 concentrations
were determined using the Human Angptl2 Assay Kit
according to the manufacturer’s instructions. Patients with
any clinically significant diseases were excluded. The full,
detailed clinical trial protocol was registered under serial
number 7-2016. A 3-mL sample of peripheral blood was
taken from both patients and controls. All blood samples

were centrifuged and stored at –20 °C for the measurement
of serum Angptl2 levels. One-way analysis of variance was
used for comparison of multiple groups. Differences of
normally and nonnormally distributed variables between
the groups were analyzed using Student’s t-test. To
assess differences in proportions, the chi-square test was
used. The predictive performance expressed as areas under
the receiver-operating characteristic curves (AUC ROCs),
sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV). All data were expressed
as the mean ± standard deviation (SD) or proportions [23].
3. Results
The control group included ten volunteers including 8
females and 2 males, their ages ranging from 15 to 20 years
old. We divided the HBV patients into three groups: Group
1 (F0–F1), “no/mild hepatic fibrosis”, included 33 patients
(41.25%), 25 of whom were male and 8 female with mean
age of 39.36 ± 11.56 years. Group 2 (F2), “significant
hepatic fibrosis”, included 9 patients (11.25%), with 8 males
and 1 female with mean age of 37.44 ± 7.7 years. Group 3
(F3–F4), “severe hepatic fibrosis and cirrhosis”, included
38 patients (47.5%), 28 of whom were males and 10 female
with mean age of 49.42 ± 10.32 years. The mean age of all
patients was 43.93 ± 11.74 years. In this study population,
61 (76.25%) were male and 19 (23.75%) were female. In
the control group, serum Angptl2 concentration was 0.93
± 0.47 ng/mL, which was different from that in patients
with no/moderate fibrosis, so early fibrosis stages could be
distinguished. With progression in the fibrosis stages, the
Angptl2 concentrations were significantly increased (P =
0.002), as seen in Table 1. Serum Angptl2 concentrations
were not just positively associated; they were also
significantly correlated with liver stiffness measurements
by Fibroscan (r = 0.249, P = 0.026). We compared Angptl2
concentrations with the commonly known noninvasive
fibrosis markers (APRI, FIB-4, and AAR). Overall, there
was a positive association between Angptl2 and APRI,
FIB-4, and AAR in the three patient groups of fibrosis, as
seen in Table 1.
Significant correlations were found between Angptl2
and age, AAR, and Fibroscan (r = 0.359, P = 0.001; r =

Table 1. Comparison between noninvasive markers at different fibrosis stages.
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Parameters

F0–F1 (n = 33)

F2 (n = 9)

F3–F4 (n = 38)

P-value

AAR

0.94 ± 0.31

0.95 ± 0.27

1.3 ± 0.58

0.003*

APRI

0.31 ± 0.1

0.80 ± 0.90

1.21 ± 1.06

<0.001*

FIB-4

0.92 ± 0.53

1.65 ± 1.80

4.13 ± 4.60

<0.001*

Fibroscan (kPa)

5.02 ± 1.03

7.77 ± 0.32

24.41 ± 17.68

<0.001*

Angptl2 (ng/mL)

1.79 ± 1.76

2.77 ± 2.71

3.02 ± 1.65

0.020*
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0.242, P = 0.031; r = 0.249, P = 0.026, respectively). Angptl2
showed areas under the receiver operating characteristic
curve of 0.702 for distinguishing patients with significant
fibrosis (F2–F4) with a sensitivity of 87.23% and NPV of
71.4% by using a cut-off value of >1.1. AUC ROCs of the
three biomarkers at different cut-offs for the diagnosis of
F2–F4 fibrosis were calculated. Angptl2 is superior to AAR
with AUCs of 70.2% and 67.8% for predicting significant
fibrosis (F ≥ 2), respectively, as presented in Table 1 and
the Figure.
When Angptl2 was combined with APRI, FIB-4, and
AAR for the assessment of significant fibrosis, AUC ROCs
were enhanced significantly (P < 0.001; Table 2).
We observed that serum levels of Angptl2 were higher
in patients who were not treated, (40%) with a mean value
of 3.08 ng/mL, compared to those receiving treatment
(60%), with a mean value of 2.1 ng/mL. We compared
Angptl2 concentrations with log10 (HBV-DNA) and
ALT levels in all HBV patients. Angptl2 levels increased
in the untreated group compared to the treated group
and both log10 (HBV-DNA) and ALT levels decreased.
Log10 HBV-DNA levels were 7.07 and 4.19, while ALT
levels were 35.51 and 29.31 in the treated group and the
untreated group, respectively. In all patients, we compared
the Angptl2 levels in the patients infected more than 1
year ago (71.25%) and the recently infected patients (<1
year) (28.75%). We found higher Angptl2 levels for older
infections (>1 year), with a value of 2.81 ng/mL, than those
for recent infections (<1 year), with a value of 1.61 ng/mL.
We observed Angptl2 levels in HBV patients with normal
levels of ALT who were not treated. In our study, we found
that despite the normal levels of ALT, the Angptl2 serum
levels were greater with higher liver fibrosis stages. For
F0–F1, the level was 2.16 ng/mL; for F2, 4.53 ng/mL; but
for F3–F4, 3.08 ng/mL. Thirty-nine (48.74%) of the HBV
patients in our study had ultrasounds. We found that in
the patients in the F0–F1 group, with bright liver, the mean
Angptl2 value was 1.88 ng/mL. Patients in the F2 group,
with chronic diffuse parenchymatous liver disease, had an

Figure. AUC of Angptl2, AST (aspartate aminotransferase) and
platelet ratio index (APRI), FIB-4 index, and AST/ALT ratio to
distinguish patients with significant fibrosis among the HBV
patients.

Angptl2 value of 2.5 ng/mL. For the patients in the F3–
F4 group, with splenomegaly and cirrhotic liver, the mean
Angptl2 value was 3.15 ng/mL.
4. Discussion
Although liver stiffness measurement (LSM) was positively
correlated with liver fibrosis stage [24], serum ALT levels
>2 times the upper limit of normal (ULN) have reduced
the accuracy of transient elastography in detecting the early
stages of fibrosis in CHB [25]. TE is only recommended for
CHB patients with normal or elevated ALT not exceeding
5-fold the ULN [26]. Angptl2 affects liver fibrosis in
HBV patients [20]. Angptl2 mRNA is expressed in the
liver and secreted by hepatocytes. Additionally, high
levels of Angptl2 protein were positively correlated with
liver cirrhosis in HCC patients [15]. Angptl2 is a central

Table 2. Diagnostic performance of noninvasive models predicting significant liver fibrosis.
Index

AUC

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

Cut-off

Angptl2

70.2%

87.23

45.45

69.5

71.4

>1.1

AAR

67.8%

72.34

63.64

73.9

61.8

>0.9

APRI

87.8%

74.47

96.97

97.2

72.7

>0.489

FIB-4

81.2%

65.96

93.94

93.9

66.0

>1.58

Combination of Angptl2 and AAR

88.75

95.74

78.79

86.54

92.86

Combination of Angptl2 and APRI

92.5

87.23

100

100

84.61

Combination of Angptl2 and FIB-4

92.5

93.62

90.91

93.62

90.91
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regulator of multiple inflammatory mediators [27],
including interleukin-6 (IL-6) and TGF-β1, found to lead to
activation of collagen expression and consequentially affect
tissue repair and fibrosis [28]. The HBx of HBV was found
to stimulate angiogenesis directly [29]. Angptl2 maintains
tissue homeostasis by inducing angiogenesis [30]. With all
this evidence, it seems reasonable to assume that Angptl2
plays a significant role in liver fibrosis in HBV patients.
Therefore, in this study including 80 HBV patients, it was
demonstrated that serum Angptl2 concentrations are
significantly correlated with LSM by Fibroscan. We found
a significant difference in the Angptl2 levels between F0–
F1 and F3–F4, which allowed us to differentiate severe
fibrosis from mild fibrosis. This is an advantage to Angptl2,
as LSM results could be considered mainly false negatives
because of macronodular cirrhosis, which is more common
in chronic hepatitis B [31]. We found a positive correlation
between Angptl2 in different fibrosis stages and APRI and
FIB-4, and a significant correlation between Angptl2 and
AAR. Detection of significant fibrosis (F ≥ 2) is the most
important clinically relevant endpoint in patients with CHB,
which indicates that patients need antiviral treatment [23].
A cut-off of Angptl2 value of >1.1 was chosen, and the AUC
of Angptl2 was 70.2%. Our results are higher compared
to a previous study [11] that showed AUCs of APRI and
FIB-4 of 0.66 and 0.63. Angptl2 was higher when it was
compared to another study, which showed AUC ROCs of
Fib-4 (0.70348), APRI (0.68627), and AAR (0.57636) for
significant fibrosis [26]. Currently, Angptl2 is superior to
AAR for the detection of significant fibrosis, with AUCs
of 70.1 and 67.8, respectively. In order to increase the
diagnostic accuracy of noninvasive tests, combined models
utilizing two or more tests have been applied for replacing
liver histology [32]. When Angptl2 was combined with
APRI, FIB-4, and AAR for assessment of significant fibrosis,
AUC ROCs were enhanced significantly. The AUC ROC of
the combination of Angptl2 and FIB-4 or Angptl2 and APRI
for predicting significant fibrosis was 0.92, significantly
superior to APRI, FIB-4, and AAR. Starting treatment for
HBV patients is a critical step. The treatment is started only
when the HBV DNA levels are above 2000 IU/mL, ALT is

>2 ULN, and active hepatic inflammation or fibrosis is seen
[33]. We observed that Angptl2 in the 3 different fibrosis
groups was always higher in the untreated group than the
treated group. By contrast, both log10 (HBV-DNA) and ALT
levels were decreased in the untreated group in comparison
with the treated group. Consequently, Angptl2 proved to be
useful to monitor the effectiveness of HBV treatment and
for use as an indicator to start treatment. Significant fibrosis
is not rare in CHB patients with normal ALT [34], so we
measured Angptl2 levels in HBV patients with normal levels
of ALT who were not treated. We found that despite normal
ALT levels, the Angptl2 concentrations were greater with
hepatic fibrosis progression. In the three different fibrosis
stages, Angptl2 levels were found higher in old infections
(>1 year) than recent infections (< 1 year), which can be an
indicator of the inflammation process, since chronic HBV
infection is a dynamic condition in which inflammatory
response via antiviral T cells arises [35]. Angptl2 proved
that it can be used successfully as an indicator of liver
fibrosis in many ways.
Angptl2 concentration levels increased with the
progression of fibrosis stages, significantly so in cases of
significant fibrosis in patients with CHB infection. The
combination of Angptl2 and FIB-4 or Angptl2 and APRI
offers an easy possibility to diagnose significant fibrosis
and its performance is superior to that of existing scores of
APRI, FIB-4, and AAR.
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